{
    "clinical_study": {
        "@rank": "67239", 
        "arm_group": [
            {
                "arm_group_label": "1000 mg/day aspirin", 
                "arm_group_type": "Experimental", 
                "description": "1000 mg/day aspirin"
            }, 
            {
                "arm_group_label": "sugar pill", 
                "arm_group_type": "Placebo Comparator", 
                "description": "sugar pill"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to determine whether aspirin is effective in\n      alleviating symptoms of the clinical high risk (CHR) syndrome for psychosis.  The\n      investigators further aim to determine whether it may delay or prevent the onset of\n      psychosis in those currently experiencing CHR symptoms.  As secondary measures the\n      investigators aim to collect laboratory studies of inflammation markers and genetic samples\n      to determine whether certain genetic profiles correlate with risk for psychosis, or response\n      to aspirin treatment."
        }, 
        "brief_title": "Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Clinical High Risk for Psychosis", 
        "condition_browse": {
            "mesh_term": [
                "Mental Disorders", 
                "Psychotic Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients will be randomly assigned to either active treatment (aspirin) or placebo."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 19 - 35\n\n          -  Must have a SIPS interview\n\n          -  CHR subjects must meet at least one of 3 CHR syndromes defined by SIPS\n\n          -  Must demonstrate adequate decisional capacity\n\n        Exclusion Criteria:\n\n          -  Under age of 19\n\n          -  Have pre-existing gastrointestinal disease, heart disease\n\n          -  Have kidney disease\n\n          -  Taking non-steroidal anti-inflammatory medications\n\n          -  Hypersensitive to NSAID\n\n          -  Have coexisting unstale major medical illness\n\n          -  Are pregnant or breastfeeding\n\n          -  Consume more than 2 drinks of alcohol per day\n\n          -  Have a blood clotting disorder\n\n          -  Are taking ACE inhibitors, acetazolamide, anticoagulants, anticonvulsants, beta\n             blockers, diuretics, methotrexate, oral hypoglycemic or uricosuric agents\n\n          -  Have a history of substance abuse in past three moths or dependence in past 6 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "35 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02047539", 
            "org_study_id": "1401013288"
        }, 
        "intervention": [
            {
                "arm_group_label": "1000 mg/day aspirin", 
                "description": "1000 mg/day of aspirin 1000 mg/day of sugar pill", 
                "intervention_name": "Aspirin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "sugar pill", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Aspirin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06519"
                }, 
                "name": "PRIME Research Clinic"
            }, 
            "investigator": {
                "last_name": "Scott W Woods, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Patients With the Clinical Risk Syndrome for Psychosis", 
        "overall_contact": {
            "email": "scott.woods@yale.edu", 
            "last_name": "Scott W Woods, MD", 
            "phone": "2039747038"
        }, 
        "overall_official": {
            "affiliation": "Yale University", 
            "last_name": "Scott W Woods, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Patients randomized to aspirin will improve significantly more on the SOPS total score than patients randomized to placebo", 
                "measure": "Scale of Prodromal Symptoms (SOPS)", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "description": "Patients randomized to aspirin will improve significantly more on the SOPS total score than patients randomized to placebo", 
                "measure": "Scale of Prodromal Symptoms (SOPS)", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Patients randomized to aspirin will improve significantly more on the SOPS total score than patients randomized to placebo", 
                "measure": "Scale of Prodromal Symptoms (SOPS)", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Patients randomized to aspirin will improve significantly more on the SOPS total score than patients randomized to placebo", 
                "measure": "Scale of Prodromal Symptoms (SOPS)", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02047539"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Yale University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}